



**THE FOUNDATION
FOR SECURE
MARKETS®**

#51619

Date: December 20, 2022

Subject: Yumanity Therapeutics, Inc. – Reverse Split/Name/Symbol/CUSIP
Change/Cash Distribution
Option Symbol: YMTX
New Symbol: KA1
Date: 12/19/2022
* * * Update * * *

Yumanity Therapeutics, Inc. (YMTX) announced it will undergo a 1-for-7 reverse stock split, and will change its name, trading symbol, and CUSIP to Kineta, Inc. (KA), CUSIP 49461C102, due to the consumation of the merger of YMTX with Kineta, Inc. on December 16, 2022.

As a result of the reverse stock split, each YMTX Common Shares will be converted into the right to receive approximately 0.142857 (New) Kineta, Inc. (KA) Common Shares. The reverse stock split will become effective before the market open on December 19, 2022. **Fractional shares will be rounded down to the nearest whole share.**

Pre-reverse split YMTX shareholders will receive a special cash dividend of \$1.43 per YMTX share payable on December 19, 2022 to shareholders of record on December 15, 2022. The ex-distribution date was also December 19, 2022.

Contract Adjustment

Effective Date: December 19, 2022

Option Symbol: YMTX changes to KA1

**Contract
Multiplier:** 1

Strike Divisor: 1

New Multiplier: 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

**New Deliverable
Per Contract:** 1) 14 Kineta, Inc. (KA) Common Shares
2) \$143.00 Cash

CUSIP: KA (New): 49461C102

Pricing

The underlying price for KA1 will be determined as follows:

$$KA1 = 0.14 (KA) + 1.43$$

Delayed Settlement

The KA component of KA1 exercise/assignment activity, which was delayed on December 19, 2022, will settle through National Security Clearing Corporation (NSCC). The \$143.00 cash amount will be settled by OCC.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.